Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
LivaNova PLC (LIVN)
NASDAQ:LIVN
LivaNova (LIVN) Stock Price & Analysis
210 Followers
LIVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$42.75 - $64.48
Previous Close$52.91
Volume525.54K
Average Volume (3M)698.18K
Market Cap
$2.87B
Enterprise Value$3.22B
Total Cash (Recent Filing)$309.19M
Total Debt (Recent Filing)$668.18M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Jul 31, 2024EPS Estimate
$0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding54,151,745
10 Day Avg. Volume785,211
30 Day Avg. Volume698,177
Standard Deviation0.11
R-Squared0.24
Alpha-0.00917
Financial Highlights & Ratios
Price to Book (P/B)15.53
Price to Sales (P/S)2.64
Price to Cash Flow (P/CF)76.20
P/FCF Ratio33.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.72
Enterprise Value/Gross Profit4.18
Enterprise Value/Ebitda139.36
Forecast
1Y Price Target
$72.14Price Target Upside32.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
LivaNova News
PremiumCompany Announcements
LivaNova’s Annual Meeting Strengthens Shareholder Alignment
PremiumCompany Announcements
LivaNova Refocuses Structure, Integrates Circulatory SupportBulls Say, Bears Say
Bulls Say
EarningsStrong $17mn/$0.24 beat in 1Q driven by outperformance in its cardiopulmonary segment.
Financial PerformanceFY24 guidance ex-ACS was raised with top-line 8-9% cc growth y/y and adj EPS $3.05-3.15.
ManagementNew CEO shaping the path forward.
Bears Say
ReimbursementThe headline RECOVER result is indicative that VNS may not clear the bar for CMS reimbursement.
Sales GrowthCardiopulmonary growth slowing sequentially due to slower heart lung machine (HLM) sales.
Study ResultsThe study missed its primary endpoint in the unipolar cohort, defined as a statistical difference between the control group and the VNS therapy group in the rate of Montgomery-Åsberg Depression Rating Scale (MADRS) response.
---
Ownership Overview
31.66% Insiders
30.59% Mutual Funds
18.15% Other Institutional Investors
19.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LIVN FAQ
What was LivaNova PLC’s price range in the past 12 months?
LivaNova PLC lowest stock price was $42.75 and its highest was $64.47 in the past 12 months.
What is LivaNova PLC’s market cap?
Currently, no data Available
When is LivaNova PLC’s upcoming earnings report date?
LivaNova PLC’s upcoming earnings report date is Jul 31, 2024 which is in 8 days.
How were LivaNova PLC’s earnings last quarter?
LivaNova PLC released its earnings results on May 01, 2024. The company reported $0.73 earnings per share for the quarter, beating the consensus estimate of $0.486 by $0.244.
Is LivaNova PLC overvalued?
According to Wall Street analysts LivaNova PLC’s price is currently Undervalued.
Does LivaNova PLC pay dividends?
LivaNova PLC does not currently pay dividends.
What is LivaNova PLC’s EPS estimate?
LivaNova PLC’s EPS estimate is $0.78.
How many shares outstanding does LivaNova PLC have?
LivaNova PLC has 54,151,745 shares outstanding.
What happened to LivaNova PLC’s price movement after its last earnings report?
LivaNova PLC reported an EPS of $0.73 in its last earnings report, beating expectations of $0.486. Following the earnings report the stock price went up 12.323%.
Which hedge fund is a major shareholder of LivaNova PLC?
Among the largest hedge funds holding LivaNova PLC’s share is PRIMECAP Management Co. It holds LivaNova PLC’s shares valued at 332M.
---
LivaNova Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$72.14 (32.95% Upside)
$72.14 (32.95% Upside)
Blogger Sentiment
Neutral
LIVN Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 725.2K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.47%
12-Months-Change
Fundamentals
Return on Equity
-2.60%
Trailing 12-Months
Asset Growth
7.18%
Trailing 12-Months
Company Description
LivaNova PLC
LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular, Neuromodulation, and Others. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The Other segment consists of company's shared service expenses for finance, legal, human resources, information technology, and new ventures. Its products include VNS therapy system. oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, and cannulae. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.
---
LIVN Company Deck
---
LIVN Earnings Call
Q1 2024
0:00 / 0:00
---
LIVN Stock 12 Month Forecast
Average Price Target
$72.14
▲(32.95% Upside)
Technical Analysis
Best Analysts Covering LIVN
1 Year
1 Year Success Rate
10/21 ratings generated profit
1 Year Average Return
-3.11%
reiterated a buy rating 2 months ago
Copying Michael Matson's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of -3.11% per trade.
---